R S Bedlack
Affiliation: Duke University Medical Center
- Amyotrophic lateral sclerosis: current practice and future treatmentsRichard S Bedlack
Neurology Section, Division of Neurology, Duke University, Durham Veterans Affairs Medical Center, Durham, North Carolina 27707, USA
Curr Opin Neurol 23:524-9. 2010..More than 1700 articles with the phrase 'amyotrophic lateral sclerosis' have been published in the past 2 years; these form the basis for this timely review...
- MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathyRichard S Bedlack
Division of Neurology, Duke University Medical Center, 932 Morreene Road, Box 3333, Durham, North Carolina 27707, USA
Muscle Nerve 29:364-8. 2004..In fact, three patients were actually treated for chronic inflammatory demyelinating polyneuropathy (CIDP). We discuss findings that may help distinguish patients with MNGIE from those with CIDP...
- Modifiable barriers to enrollment in American ALS research studiesRichard S Bedlack
Duke University and Durham Veterans Affairs Medical Center, 932 Morreene Rd, Durham, NC 27702, USA
Amyotroph Lateral Scler 11:502-7. 2010..Also included are patient concerns about the cost of participation, and confusion about several aspects of studies being offered. Along with prior work, these data suggest specific steps that can be taken to improve enrollment...
- Complementary and Alternative Therapies in Amyotrophic Lateral SclerosisRichard S Bedlack
Department of Neurology, Duke University Medical Center, Durham, NC 27702, USA Electronic address
Neurol Clin 33:909-36. 2015..Finally, the authors review a program called ALSUntangled, which uses shared decision making to review alternative therapies for ALS. ..
- Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron diseaseRichard S Bedlack
Duke University Medical Center, Durham, North Carolina 27702, USA
Amyotroph Lateral Scler 10:210-5. 2009....
- How to handle myasthenic crisis. Essential steps in patient careR S Bedlack
Duke University School of Medicine, Durham, North Carolina 27713, USA
Postgrad Med 107:211-4, 220-2. 2000..Because management of crisis includes treatment of the underlying myasthenia gravis, a neurologist should share in any decisions regarding care...
- Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosisRichard S Bedlack
Duke University Medical Center, Box 3333, Durham NC 27705, USA
Expert Opin Emerg Drugs 12:229-52. 2007..These are described and prioritized herein, and suggestions are offered for efficiently sifting through them...
- Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validityR S Bedlack
Duke University Medical Center and Durham VAMC, Durham, NC, USA
Neurology 64:1968-70. 2005..Our results support QMG use for assessing clinical change in trials...
- Apolipoprotein E and neuromuscular disease: a critical review of the literatureR S Bedlack
PO Box 3403, Duke University Medical Center, Durham, NC 27710, USA
Arch Neurol 57:1561-5. 2000..The effect of various APOE alleles on neuromuscular diseases therefore parallels their influence on central nervous system diseases. Arch Neurol. 2000;57:1561-1565..
- APOE genotype is a risk factor for neuropathy severity in diabetic patientsR S Bedlack
Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
Neurology 60:1022-4. 2003..Considering genotype alone, patients with APOE 3/4 and 4/4 genotypes had 3 more NISLL points than patients with other genotypes. This impact on severity is equivalent to having 15 extra years of age or diabetes duration...
- Does this patient have myasthenia gravis?Katalin Scherer
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
JAMA 293:1906-14. 2005..Clinicians must be able to diagnose myasthenia gravis, since delays in establishing the diagnosis may put patients at risk for complications from this treatable disease...
- Factors associated with survival in the National Registry of Veterans with ALSDaniel M Pastula
School of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Amyotroph Lateral Scler 10:332-8. 2009..This finding could be due to a common exposure, a shared characteristic, an unmeasured confounder, or an enrollment bias. More research will be needed to understand the reasons behind this new finding...
- The National Registry of Veterans with amyotrophic lateral sclerosisK D Allen
Epidemiology Research and Information Center, Durham VAMC, NC 27705, USA
Neuroepidemiology 30:180-90. 2008..This article describes the objectives, methods, and sample involved in the registry...
- Steroid treatment for myasthenia gravis: steroids have an important roleRichard S Bedlack
Division of Neurology, Duke University Medical Center, Trent Drive, Room 0395, Box 3403, Durham, North Carolina 27710 0001, USA
Muscle Nerve 25:117-21. 2002
- Scrutinizing enrollment in ALS clinical trials: room for improvement?Richard S Bedlack
Duke University Medical Center, Durham, NC, USA
Amyotroph Lateral Scler 9:257-65. 2008..Patient factors' and 'physician factors' may play more important roles in influencing enrollment, as in oncology trials. Our survey data support this idea, and provide potential mechanisms for improving enrollment...
- Amyotrophic lateral sclerosis: an emerging era of collaborative gene discoveryKatrina Gwinn
National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 2:e1254. 2007..This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS...
- Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRSJeffrey Rosenfeld
The Carolinas Neuromuscular ALS Center, Charlotte North Carolina, Carolinas Medical Center, USA
Amyotroph Lateral Scler 9:266-72. 2008..The trend toward improved survival was also found in another recently completed blinded trial using creatine monohydrate. Further investigation on the possible survival benefit of creatine in this patient population is ongoing...
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz
Neurology Clinical Trials Unit, Massachusetts General Hospital, 13th Street, Charlestown, MA 02129, USA
Muscle Nerve 38:837-44. 2008..Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned...
- Lithium may slow progression of amyotrophic lateral sclerosis, but further study is neededRichard S Bedlack
Proc Natl Acad Sci U S A 105:E17; author reply E18. 2008
- Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialPaul H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Lancet Neurol 6:1045-53. 2007..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)...
- Dysarthria and dysphagia from light chain amyloidosisKhalid Tabbarah
Division of Neurology, Department of Medicine, Duke University Medical Center, PO Box 2905, Durham, NC 27710, USA
Neurology 65:1671. 2005